International data
Below is the latest international comparison of Covid-19 data using WHO published figures. As mentioned before, country to country comparison has some limitations because of the variation in approach, data collection and testing.
Data from 23/07/2020:
Cases |
Deaths |
Death rate |
||
1 |
USA |
3,868,453 |
141,479 |
3.7% |
2 |
Brazil |
2,159,654 |
81,487 |
3.8% |
3 |
India |
1,238,635 |
29,861 |
2.4% |
4 |
Russia |
795,038 |
12,892 |
1.6% |
5 |
South Africa |
394,948 |
5,940 |
1.5% |
6 |
Peru |
362,087 |
13,579 |
3.8% |
7 |
Mexico |
356,255 |
40,400 |
11.3% |
8 |
Chile |
336,402 |
8,722 |
2.6% |
9 |
UK |
296,381 |
45,501 |
15.4% |
10 |
Iran |
281,413 |
14,853 |
5.3% |
11 |
Pakistan |
269,191 |
5,709 |
2.1% |
International policy updates
Global
Europe
Africa
North America
South America
Middle East
Asia
Australia
International spotlight on… the vaccine race
According to a statement published by the Business Secretary, Alok Sharma, there will be an additional “£100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the U.K.”. In practice that means a new Cell and Gene Therapy Catapult Manufacturing Innovation Centre.
Following a $2bn deal with Pfizer Inc and German biotech BioNTech SE, the US has set a benchmark for COVID-19 vaccine pricing. The deal secures enough vaccines to inoculate 50 million Americans for about $40 per person (or the price of an annual flu shot). This is part of the U.S government’s Operation Warp Speed programme, which seeks to nurture a government-industry partnership. The UK has also signed a deal to secure 30 million doses of this vaccine (which injects part of the coronavirus’ genetic code).
There are currently more than 165 vaccines against coronavirus in development, 27 of which are in the human trial stage. Three of those are in the Phase III stage, and most recently a vaccine developed by the University of Oxford appears safe and triggers an immune response. The UK has ordered 100 million doses of this vaccine.
The key is to ensure that any vaccine that is proven to be substantially effective can be administered at scale across the country, and the world. Gavi, the vaccine alliance, is co-leading a global effort to ensure that any response to COVID-19 is effective and fair, primarily by identifying and rapidly accelerating development, production and delivery of COVID-19 vaccines so that anyone that needs them, gets them. At the end of April, the WHO developed the Access to Covid-19 Tools (ACT) accelerator, this is a framework for collaboration (not a decision-making body) that aims to support the development and equitable distribution of the diagnostics, vaccines and treatments the world needs. 14 countries and the European Commission have so far committed to the accelerator, and the Economist Intelligence Unit have developed a COVID-19 Health Funding tracker to independently track pledges, allocations, disbursements of funding for the global health response to COVID-19, as a way to provide an independent record of which funders are funding which aspects of the global health response. The tracker will help increase accountability and target further pledges towards critical funding gaps.